Biotech entity
fda-approval is the sole category represented across all 1 tracked stories. daraxonrasib is most often covered alongside Brian Wolpin, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention daraxonrasib, all published on August 27, 2026.
Last mentioned: 6h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
fda-approval is the sole category represented across all 1 tracked stories. daraxonrasib is most often covered alongside Brian Wolpin, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention daraxonrasib, all published on August 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering daraxonrasib. Shared-story counts are live from our verified record — not editorial picks.
For biotech and pharma professionals, Revolution Medicines' daraxonrasib becomes the first approved multi-RAS inhibitor, with Phase 3 median overall survival of 13.2 months vs 6.6 on chemo, validating the RAS(ON) platform and opening a new commercial front in pancreatic cancer.
Source: ABCNews (US) · Madeline Halpert (gb)
daraxonrasib is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
